Featured Research

from universities, journals, and other organizations

Epigenetic causes of prostate cancer: Researchers observe modified methylation patterns in a group of prostate cancers

Date:
September 5, 2012
Source:
Max-Planck-Gesellschaft
Summary:
In about half of all prostate tumors, there are two genetic areas that are fused with one another. When this is not the case, the exact way cancer cells originate in prostate tumors was not clear until now. Scientists were able to show that the genesis of this fusion-negative prostate cancer has epigenetic causes: methyl groups are distributed differently over the DNA in the cancer cells than in healthy cells. Thanks to this knowledge, physicians may be able to achieve greater specificity in treating prostate tumors in future. In addition, the aberrant DNA methylations can be used as a potential biomarker for identifying prostate cancer.

In about half of all prostate tumours, there are two genetic areas that are fused with one another. When this is not the case, the exact way cancer cells originate in prostate tumours was not clear until now.

Related Articles


Scientists at the Max Planck Institute for Molecular Genetics in Berlin, in cooperation with a team of international researchers, were able to show that the genesis of this fusion-negative prostate cancer has epigenetic causes: methyl groups are distributed differently over the DNA in the cancer cells than in healthy cells. Thanks to this knowledge, physicians may be able to achieve greater specificity in treating prostate tumours in future. In addition, the aberrant DNA methylations can be used as a potential biomarker for identifying prostate cancer.

About half of all cases of prostate cancer originate through fusion of two genetic areas. As a result, the ERG gene is activated in these fusion-positive cells and prostate cells propagate, leading to tumourigenesis. Fusion-positive prostate cancer can be treated with PARP1 inhibitors that turn off the repair system of the tumour cells.

However, it has not been clear how prostate tumours without a fused ERG gene acquire their tumourigenic potential. Now, a team of Max Planck scientists headed by Michal-Ruth Schweiger from the Department of Vertebrate Genomics have investigated the global DNA methylation pattern -- i.e. at which locations the DNA possesses methyl groups -- in fusion-negative tumours. They have discovered that, compared to fusion-positive tumours, the fusion-negative tumours display more aberrant DNA methylations, which are most likely causative for the malignant transformation of prostate cells.

Moreover, the scientists found large amounts of the enzyme EZH2 in the cells of the tumours. This histone methyltransferase couples histone and DNA methylation and also transfers methyl groups to the DNA. Further functional analyses link EZH2 to the aberrant DNA methylations in fusion gene negative tumours. As reason for the significantly increased amount of EZH2 the scientists found very low concentrations of miRNA-26a, a micro-RNA that targets EZH2 for degradation.

The researchers think that their findings will further enhance diagnosis and specific treatment options for prostate cancer patients. "Regions with different DNA-methylation patterns can be used as biomarkers to diagnose specific subgroups of cancer," says Schweiger. "In addition, new medications for fusion-negative prostate cancer could operate with greater specificity and therefore be more effective." It is likely that other types of cancer are also based on these kinds of pronounced epigenetic modifications.


Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. T. Borno, A. Fischer, M. Kerick, M. Falth, M. Laible, J. C. Brase, R. Kuner, A. Dahl, C. Grimm, B. Sayanjali, M. Isau, C. Rohr, A. Wunderlich, B. Timmermann, R. Claus, C. Plass, M. Graefen, R. Simon, F. Demichelis, M. A. Rubin, G. Sauter, T. Schlomm, H. Sultmann, H. Lehrach, M.-R. Schweiger. Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation.. Cancer Discovery, 2012; DOI: 10.1158/2159-8290.CD-12-0041

Cite This Page:

Max-Planck-Gesellschaft. "Epigenetic causes of prostate cancer: Researchers observe modified methylation patterns in a group of prostate cancers." ScienceDaily. ScienceDaily, 5 September 2012. <www.sciencedaily.com/releases/2012/09/120905083857.htm>.
Max-Planck-Gesellschaft. (2012, September 5). Epigenetic causes of prostate cancer: Researchers observe modified methylation patterns in a group of prostate cancers. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2012/09/120905083857.htm
Max-Planck-Gesellschaft. "Epigenetic causes of prostate cancer: Researchers observe modified methylation patterns in a group of prostate cancers." ScienceDaily. www.sciencedaily.com/releases/2012/09/120905083857.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins